Skip to main
ARAY

Accuray (ARAY) Stock Forecast & Price Target

Accuray (ARAY) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Accuray is poised for growth as the demand for radiation therapy continues to rise in the healthcare industry. The company's innovative technology, the CyberKnife, sets the standard for precise and effective radiation treatment for cancer and tumors. Despite a decrease in forecasted revenue and higher costs, the company's strong product and service offerings make it a sound investment for the future.

Bears say

Accuray is facing geopolitical headwinds and delays in shipping to certain regions, leading to decreased product and service revenue forecasts for the future. While the company has appointed a new executive and is working on expanding its service portfolio and distributor partnerships, the current uncertainty makes it difficult to predict when these initiatives will take effect. With a lack of progress in commercial execution and profitability metrics, coupled with a lengthy timeline for potential operational improvements, it is recommended to take a neutral stance on Accuray's stock.

Accuray (ARAY) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Accuray and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Accuray (ARAY) Forecast

Analysts have given Accuray (ARAY) a Buy based on their latest research and market trends.

According to 2 analysts, Accuray (ARAY) has a Buy consensus rating as of Aug 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1.18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1.18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Accuray (ARAY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.